Substance / Medication

Delafloxacin

Overview

Active Ingredient
delafloxacin
RxNorm CUI
1927663

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis.
Vlachaki Ioanna, Vacchelli Matteo, Zinzi Daniela et al. · BMC Infect Dis · 2021
PMID: 34610820Meta-AnalysisFull text (PMC)
Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover Randall, Hunt Thomas, Benedict Michael et al. · Clin Ther · 2016
PMID: 26718605RCT
Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Hoover Randall, Hunt Thomas, Benedict Michael et al. · Clin Ther · 2016
PMID: 26581327RCT
A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.
Litwin Jeffrey S, Benedict Michael S, Thorn Michael D et al. · Antimicrob Agents Chemother · 2015
PMID: 25845864RCTFull text (PMC)
Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization.
Lv Jiong-Xian, Huang Yi-Huan, Kafauit Farah et al. · Antimicrob Agents Chemother · 2024
PMID: 38899925TrialFull text (PMC)
Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Bassetti Matteo, Hooper David, Tillotson Glenn · Clin Infect Dis · 2019
PMID: 30957169TrialFull text (PMC)
Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Giordano Philip A, Pogue Jason M, Cammarata Sue · Clin Infect Dis · 2019
PMID: 30957167TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Delafloxacin (substance)
SNOMED CT
735011001
UMLS CUI
C2828290
RxNorm CUI
1927663

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

7
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Delafloxacin: Uses, Evidence & Side Effects | Ltrl